Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
After several setbacks in 2010, the Swiss Pharma lowers its guidance on its best-selling drug and braces for the results from a key study.
You may also be interested in...
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
If the ophthalmic product wins priority review, Roche could see competition for Lucentis in wet AMD by the fall.